Sunitinib in the Treatment of Advanced Solid Tumors
| Autor: | Daniel Y.C. Heng, Amal Imbulgoda, Christian Kollmannsberger |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
GiST
biology Sunitinib business.industry Medullary thyroid cancer Neuroendocrine tumors urologic and male genital diseases medicine.disease Clear cell renal cell carcinoma Growth factor receptor Renal cell carcinoma medicine biology.protein Cancer research business Platelet-derived growth factor receptor medicine.drug |
| Zdroj: | Recent Results in Cancer Research ISBN: 9783642544897 |
| Popis: | Sunitinib is an oral multikinase inhibitor that blocks the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-kit, and other receptors. These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC), unresectable gastrointestinal stromal tumors (GIST), and well-differentiated advanced pancreatic neuroendocrine tumors (PNET). Though activity has been reported in other tumor types, phase III trials have not yet demonstrated improved survival outcomes in these cancers. Most side effects including hypertension, hand-foot syndrome, and diarrhea are generally well manageable. This review will detail the preclinical data leading up to the results of the pivotal phase III clinical trials that have led to the widespread use of sunitinib in advanced RCC, GIST, and PNET. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|